Biosimilar Monoclonal Antibodies Market to Grow with a CAGR of 12.03% through 2030
The expiration
of patents for major biologic drugs, coupled with the growing adoption of
cost-effective biosimilars, is expected to drive the Global Biosimilar
Monoclonal Antibodies Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Biosimilar Monoclonal Antibodies Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Biosimilar Monoclonal Antibodies Market stood at USD 5.47 Billion in
2024 and is expected to reach USD 10.83 Billion by 2030 with a CAGR of 12.03% during
the forecast period. With ongoing advancements in biotechnology and manufacturing
processes, we can expect to see improvements in the quality and consistency of
biosimilar products. As regulatory pathways continue to evolve and gain
acceptance, the market is likely to expand further, creating more opportunities
for both established players and newcomers. As the biosimilar mAbs market
matures, it has the potential to reshape healthcare by providing cost-effective
treatment options to a broader patient population. This could lead to reduced
healthcare costs, improved patient access, and enhanced healthcare
sustainability. The biosimilar
monoclonal antibodies market is witnessing a surge in growth, driven by rising
regulatory support, technological advancements, and the need for cost-effective
therapeutic options. The strict evaluation processes set by regulatory agencies
have instilled confidence in the safety and efficacy of these products. As the
market continues to expand, patients, healthcare professionals, and governments
stand to benefit from increased access to high-quality treatments at more
affordable prices.
However, developing
biosimilar monoclonal antibodies requires substantial investments in research
and development, clinical trials, and manufacturing capabilities. Additionally,
ensuring interchangeability with reference products and overcoming physician
and patient hesitancy pose ongoing hurdles, which may hamper the growth of the
market in the projected period.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on " Global Biosimilar Monoclonal Antibodies Market.”
The Global
Biosimilar Monoclonal Antibodies is segmented into product, application, regional
distribution, and company.
Based on the Application,
Oncology emerged as the fastest growing segment in the Global Biosimilar
Monoclonal Antibodies Market during the forecast period. This is due to the
increasing prevalence of cancer and the growing demand for effective and
affordable treatments. Cancer therapies, particularly monoclonal antibodies
(mAbs), have become a cornerstone in the management of various types of cancer,
including breast cancer, colorectal cancer, and non-small cell lung cancer.
However, the high cost of reference biologics has limited access to these
life-saving treatments for many patients.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Biosimilar Monoclonal Antibodies Market during
the forecast period. This is due to several key factors, including the high
burden of chronic diseases, rising healthcare costs, and an expanding patient
population. The region is home to a significant number of individuals suffering
from chronic and autoimmune diseases, such as cancer, rheumatoid arthritis, and
diabetes, creating a substantial demand for biologic therapies. However, the
high cost of reference biologics has made access to treatments limited in many
Asia-Pacific countries. Biosimilars
present a more affordable alternative to reference biologics, enabling
healthcare systems in countries like India, China, and South Korea to expand
access to life-saving treatments. The growing healthcare infrastructure,
supportive government policies, and increasing acceptance of biosimilars among
healthcare professionals and patients have further accelerated the adoption of
biosimilars in the region.
Major
companies operating in Global Biosimilar Monoclonal Antibodies market
are:
- Abbott
- Pfizer
- Novartis AG
- AbbVie, Inc.
- Coherus BioSciences
- Biocon Limited
- Allergan plc.
- Accord Healthcare limited.
- Amgen inc.
- Dr. Reddy’s Laboratory
Download Free Sample Report
Customers can also request
for 10% free customization on this report
“The Global
Biosimilar Monoclonal Antibodies Market is expanding due to the increasing
demand for cost-effective cancer treatments, the growing prevalence of chronic
and autoimmune diseases, and the rising adoption of biosimilars in both
developed and emerging markets. As patents for blockbuster biologics continue
to expire, biosimilars are gaining traction due to their ability to offer
similar therapeutic benefits at a fraction of the cost, enhancing patient
access to life-saving therapies. Additionally, the expanding healthcare
infrastructure and favorable regulatory frameworks in regions like Asia-Pacific
and Latin America are further contributing to market growth. These factors are
driving significant investment and innovation within the biosimilar sector.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Biosimilar Monoclonal
Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Product (Infliximab, Rituximab, Abciximab, Trastuzumab,
Adalimumab, Bevacizumab, Others), By Application (Oncology, Chronic & Autoimmune
Diseases, Others), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Biosimilar Monoclonal
Antibodies Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Biosimilar
Monoclonal Antibodies Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com